A phase I study of S-222611 an oral reversible dual inhibitor of EGFR and HER2, in patients with solid tumors.
暂无分享,去创建一个
R. Plummer | E. Frenkel | M. Jamal-Hanjani | J. Spicer | D. Jodrell | J. Posner | R. Baird | L. Hogarth | S. Papa | H. Hatcher | N. Cresti | K. Donaldson | I. Kawabata